Could Amgen soften the Neulasta biosimilar blow with an Alexion buy?

Amgen is staring down some major competitive threats to some of its biggest sellers, meaning an acquisition could be in order. And some industry watchers have just the target in mind.
Read the full story: FiercePharma: Pharma